Molecular Partners AG (MOLN)
3.85
+0.04
(+1.05%)
USD |
NASDAQ |
Oct 09, 16:00
3.81
-0.04
(-1.04%)
After-Hours: 20:00
Molecular Partners Enterprise Value : 67.03M for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 67.03M |
| October 08, 2026 | 65.50M |
| October 07, 2026 | 65.50M |
| October 06, 2026 | 64.35M |
| October 05, 2026 | 69.72M |
| October 02, 2026 | 69.33M |
| October 01, 2026 | 69.33M |
| September 30, 2026 | 69.33M |
| September 29, 2026 | 68.95M |
| September 28, 2026 | 67.42M |
| September 25, 2026 | 84.27M |
| September 24, 2026 | 84.27M |
| September 23, 2026 | 84.27M |
| September 22, 2026 | 82.74M |
| September 21, 2026 | 72.40M |
| September 18, 2026 | 80.82M |
| September 17, 2026 | 69.72M |
| September 16, 2026 | 69.72M |
| September 15, 2026 | 80.44M |
| September 14, 2026 | 73.55M |
| September 11, 2026 | 79.67M |
| September 10, 2026 | 79.67M |
| September 09, 2026 | 86.19M |
| September 08, 2026 | 86.19M |
| September 04, 2026 | 86.19M |
| Date | Value |
|---|---|
| September 03, 2026 | 86.19M |
| September 02, 2026 | 75.46M |
| September 01, 2026 | 83.70M |
| August 31, 2026 | 91.93M |
| August 28, 2026 | 91.93M |
| August 27, 2026 | 97.77M |
| August 26, 2026 | 90.02M |
| August 25, 2026 | 87.34M |
| August 24, 2026 | 88.10M |
| August 21, 2026 | 88.10M |
| August 20, 2026 | 81.59M |
| August 19, 2026 | 85.42M |
| August 18, 2026 | 83.89M |
| August 17, 2026 | 82.36M |
| August 14, 2026 | 80.82M |
| August 13, 2026 | 80.82M |
| August 12, 2026 | 77.76M |
| August 11, 2026 | 77.76M |
| August 10, 2026 | 77.76M |
| August 07, 2026 | 74.70M |
| August 06, 2026 | 74.70M |
| August 05, 2026 | 78.91M |
| August 04, 2026 | 78.91M |
| August 03, 2026 | 77.38M |
| July 31, 2026 | 70.10M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Kuros Biosciences Ltd. | 944.14M |
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| BeOne Medicines Ltd. | 33.72B |
| AC Immune SA | 139.41M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -17.16M |
| Total Expenses (Quarterly) | 17.16M |
| EPS Diluted (Quarterly) | -0.4479 |
| Earnings Yield | -44.51% |
| Normalized Earnings Yield | -44.47 |